探索植物性营养药在治疗糖尿病神经病变时的有效性
Samea Khan1, Maria Markoulli1, Amy T Tsoi2
1School of Optometry and Vision Science, University of New South Wales, Sydney, NSW, 2052, Australia.
Inflammopharmacology
|May 28, 2025
概括
植物性营养药在治疗糖尿病神经病变方面表现有前途,通过改善神经功能和减少大鼠模型中的疼痛行为来改善神经功能. 建议使用标准化方法进行进一步的研究.
科学领域:
- 药理学 药理学是指药理学的学科.
- 神经学 神经学
- 自然产品研究 自然产品研究
背景情况:
- 糖尿病外围神经病变是一种常见的糖尿病并发症.
- 植物性天然产品正在研究其治疗潜力.
- 需要有效的糖尿病神经病变管理策略.
研究的目的:
- 系统地审查和元分析植物性营养药对大鼠模型中的糖尿病神经病变的治疗疗效.
- 评估这些天然产品对神经传导速度和疼痛行为的影响.
- 为了确定潜在的作用机制.
主要方法:
- 在2023年11月在PubMed和Scopus上进行的系统文献审查.
- 使用随机效应模型对18项研究的元分析.
- 主要结局措施包括神经传导速度和与疼痛相关的行为 (热和机械手足撤出延迟).
主要成果:
- 植物提取物和分离化合物显著改善了神经传导速度.
- 观察到热和机械爪撤回延迟的显著增加.
- 建议的机制包括减少炎症性细胞因子和氧化应激.
结论:
- 在临床前模型中,植物性疗法在治疗糖尿病引起的外周神经病变方面表现出有效性.
- 需要对标准化实验设计和报告进行进一步的研究来证实这些发现.
相关概念视频
Diabetes: Management and Pharmacotherapy
412
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
412
Pathophysiology of Diabetes
1.3K
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
1.3K
Peripheral Artery Disease IV: Nursing Management
48
The nursing management of a patient with peripheral artery disease (PAD) begins with a thorough assessment of the patient’s health history and clinical manifestations.AssessmentHealth History: Evaluate the patient’s history of hypertension, hyperlipidemia, family history of cardiovascular issues, and lifestyle factors such as dietary patterns, smoking, and physical activity.Physical Examination:Assess the affected extremity for decreased or absent peripheral pulses,...
48
Atherosclerosis III: Management
42
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
42
Oral Hypoglycemic Agents: Biguanides and Glitazones
310
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
310
Oral Hypoglycemic Agents: Glinides
274
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
274


